Article

Patients with Undiagnosed Diabetes Have Worse Short-Term Cardiac Outcomes

Patients who are unaware that they have diabetes may have less contact with healthcare professionals, receive less aggressive treatment, or have a poorer understanding of the disease and the actions required to treat it - all of which may be responsible for their increased risk of morbidity and mortality.

In addition to the 18 million Americans who have diabetes, 35 percent of the population is prediabetic and 7 million Americans have undiagnosed diabetes. Elevated glucose levels at hospital admission and delayed diabetes diagnosis are both associated with worse long-term outcomes for patients. Patients who are unaware that they have diabetes may have less contact with healthcare professionals, receive less aggressive treatment, or have a poorer understanding of the disease and the actions required to treat it — all of which may be responsible for their increased risk of morbidity and mortality.

In a recent study published in the American Heart Journal, a group of international researchers examined the outcomes of 8,795 high-risk, non—ST-segment elevation (NSTE) patients enrolled in an acute coronary syndrome (ACS) trial for prediabetes, previously undiagnosed diabetes, or diabetes. The authors found that 12 percent of the patient population had undiagnosed diabetes and 11 percent had prediabetes.

Thirty days after ACS, the undiagnosed diabetics had increased rates of all-cause death or myocardial infarction. However, at the one year mark, mortality was not elevated in that patient group, and the event rates for prediabetics were similar to those of non-diabetic patients at 30 days and 12 months.

In light of the poor short-term outcomes among the undiagnosed diabetics, the authors recommended increased routine screening for diabetes in order to implement management strategies early.

Related Videos
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
Viet Le, DMSc, PA-C | Credit: APAC
Marianna Fontana, MD, PhD: Declines in Kidney Function Frequent in ATTR-CM  | Image Credit: Radcliffe Cardiology
© 2024 MJH Life Sciences

All rights reserved.